带有 shRNA-IL-6 基因沉默元件的安全有效的抗 CD19 CAR T 细胞用于难治或复发 B 细胞急性淋巴细胞白血病患者。

IF 7.6 2区 医学 Q1 HEMATOLOGY HemaSphere Pub Date : 2024-10-07 DOI:10.1002/hem3.70007
Jin-Feng Ma, Jia-Wei Yan, Mei-Jing Liu, Chun-Long Yan, Xiao-Wen Tang, Hui-Ying Qiu, Miao Miao, Yue Han, Li-Min Li, Li-Qing Kang, Nan Xu, Zhou Yu, Jing-Wen Tan, Hong-Jia Zhu, Xu Jia, Zhi-Zhi Zhang, Miao Wang, Hai-Ping Dai, Lei Yu, Sheng-Li Xue, De-Pei Wu, Wen-Jie Gong
{"title":"带有 shRNA-IL-6 基因沉默元件的安全有效的抗 CD19 CAR T 细胞用于难治或复发 B 细胞急性淋巴细胞白血病患者。","authors":"Jin-Feng Ma,&nbsp;Jia-Wei Yan,&nbsp;Mei-Jing Liu,&nbsp;Chun-Long Yan,&nbsp;Xiao-Wen Tang,&nbsp;Hui-Ying Qiu,&nbsp;Miao Miao,&nbsp;Yue Han,&nbsp;Li-Min Li,&nbsp;Li-Qing Kang,&nbsp;Nan Xu,&nbsp;Zhou Yu,&nbsp;Jing-Wen Tan,&nbsp;Hong-Jia Zhu,&nbsp;Xu Jia,&nbsp;Zhi-Zhi Zhang,&nbsp;Miao Wang,&nbsp;Hai-Ping Dai,&nbsp;Lei Yu,&nbsp;Sheng-Li Xue,&nbsp;De-Pei Wu,&nbsp;Wen-Jie Gong","doi":"10.1002/hem3.70007","DOIUrl":null,"url":null,"abstract":"<p>Severe cytokine release syndrome (sCRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) have limited the widespread use of chimeric antigen receptor T (CAR T)-cell therapy. We designed a novel anti-CD19 CAR (ssCART-19) with a small hairpin RNA (shRNA) element to silence the interleukin-6 (IL-6) gene, hypothesizing it could reduce sCRS and ICANS by alleviating monocyte activation and proinflammatory cytokine release. In a post hoc analysis of two clinical trials, we compared ssCART-19 with common CAR T-cells (cCART-19) in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). Among 87 patients, 47 received ssCART-19 and 40 received cCART-19. Grade ≥3 CRS occurred in 14.89% (7/47) of the ssCART-19 group versus 37.5% (15/40) in the cCART-19 group (<i>p</i> = 0.036). ICANS occurred in 4.26% (2/47) of the ssCART-19 group (all grade 1) compared to 15% (2/40) of the cCART-19 group. Patients in the ssCART-19 group showed comparable rates of treatment response (calculated with rates of complete remission and incomplete hematological recovery) were 91.49% (43/47) for ssCART-19 and 85% (34/40) for cCART-19 (<i>p</i> = 0.999). With a median follow-up of 21.9 months, cumulative nonrelapse mortality was 10.4% for ssCART-19 and 13.6% for cCART-19 (<i>p</i> = 0.33). Median overall survival was 37.17 months for ssCART-19 and 32.93 months for cCART-19 (<i>p</i> = 0.40). Median progression-free survival was 24.17 months for ssCART-19 and 9.33 months for cCART-19 (<i>p</i> = 0.23). These data support the safety and efficacy of ssCART-19 for r/r B-ALL, suggesting its potential as a promising therapy.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":null,"pages":null},"PeriodicalIF":7.6000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11456753/pdf/","citationCount":"0","resultStr":"{\"title\":\"Safe and potent anti-CD19 CAR T-cells with shRNA-IL-6 gene silencing element in patients with refractory or relapsed B-cell acute lymphoblastic leukemia\",\"authors\":\"Jin-Feng Ma,&nbsp;Jia-Wei Yan,&nbsp;Mei-Jing Liu,&nbsp;Chun-Long Yan,&nbsp;Xiao-Wen Tang,&nbsp;Hui-Ying Qiu,&nbsp;Miao Miao,&nbsp;Yue Han,&nbsp;Li-Min Li,&nbsp;Li-Qing Kang,&nbsp;Nan Xu,&nbsp;Zhou Yu,&nbsp;Jing-Wen Tan,&nbsp;Hong-Jia Zhu,&nbsp;Xu Jia,&nbsp;Zhi-Zhi Zhang,&nbsp;Miao Wang,&nbsp;Hai-Ping Dai,&nbsp;Lei Yu,&nbsp;Sheng-Li Xue,&nbsp;De-Pei Wu,&nbsp;Wen-Jie Gong\",\"doi\":\"10.1002/hem3.70007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Severe cytokine release syndrome (sCRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) have limited the widespread use of chimeric antigen receptor T (CAR T)-cell therapy. We designed a novel anti-CD19 CAR (ssCART-19) with a small hairpin RNA (shRNA) element to silence the interleukin-6 (IL-6) gene, hypothesizing it could reduce sCRS and ICANS by alleviating monocyte activation and proinflammatory cytokine release. In a post hoc analysis of two clinical trials, we compared ssCART-19 with common CAR T-cells (cCART-19) in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). Among 87 patients, 47 received ssCART-19 and 40 received cCART-19. Grade ≥3 CRS occurred in 14.89% (7/47) of the ssCART-19 group versus 37.5% (15/40) in the cCART-19 group (<i>p</i> = 0.036). ICANS occurred in 4.26% (2/47) of the ssCART-19 group (all grade 1) compared to 15% (2/40) of the cCART-19 group. Patients in the ssCART-19 group showed comparable rates of treatment response (calculated with rates of complete remission and incomplete hematological recovery) were 91.49% (43/47) for ssCART-19 and 85% (34/40) for cCART-19 (<i>p</i> = 0.999). With a median follow-up of 21.9 months, cumulative nonrelapse mortality was 10.4% for ssCART-19 and 13.6% for cCART-19 (<i>p</i> = 0.33). Median overall survival was 37.17 months for ssCART-19 and 32.93 months for cCART-19 (<i>p</i> = 0.40). Median progression-free survival was 24.17 months for ssCART-19 and 9.33 months for cCART-19 (<i>p</i> = 0.23). These data support the safety and efficacy of ssCART-19 for r/r B-ALL, suggesting its potential as a promising therapy.</p>\",\"PeriodicalId\":12982,\"journal\":{\"name\":\"HemaSphere\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2024-10-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11456753/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"HemaSphere\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hem3.70007\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"HemaSphere","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hem3.70007","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

严重细胞因子释放综合征(sCRS)和免疫效应细胞相关神经毒性综合征(ICANS)限制了嵌合抗原受体T(CAR T)细胞疗法的广泛应用。我们设计了一种新型抗 CD19 CAR(ssCART-19),它带有小发夹 RNA(shRNA)元件以沉默白细胞介素-6(IL-6)基因,并假设它可以通过减轻单核细胞活化和促炎细胞因子释放来减轻 sCRS 和 ICANS。在对两项临床试验进行的事后分析中,我们对复发/难治性 B 细胞急性淋巴细胞白血病(r/r B-ALL)的 ssCART-19 和普通 CAR T 细胞(cCART-19)进行了比较。在87名患者中,47人接受了ssCART-19治疗,40人接受了cCART-19治疗。ssCART-19组有14.89%(7/47)发生≥3级CRS,而cCART-19组为37.5%(15/40)(p = 0.036)。ssCART-19组有4.26%(2/47)的患者发生ICANS(均为1级),而cCART-19组为15%(2/40)。ssCART-19组患者的治疗反应率(以完全缓解率和不完全血液学恢复率计算)相当,ssCART-19组为91.49%(43/47),cCART-19组为85%(34/40)(P = 0.999)。中位随访时间为 21.9 个月,ssCART-19 的累积非复发死亡率为 10.4%,cCART-19 为 13.6%(p = 0.33)。ssCART-19的中位总生存期为37.17个月,cCART-19为32.93个月(p = 0.40)。ssCART-19 的中位无进展生存期为 24.17 个月,cCART-19 为 9.33 个月(p = 0.23)。这些数据支持ssCART-19治疗r/r B-ALL的安全性和有效性,表明它有可能成为一种前景广阔的疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Safe and potent anti-CD19 CAR T-cells with shRNA-IL-6 gene silencing element in patients with refractory or relapsed B-cell acute lymphoblastic leukemia

Severe cytokine release syndrome (sCRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) have limited the widespread use of chimeric antigen receptor T (CAR T)-cell therapy. We designed a novel anti-CD19 CAR (ssCART-19) with a small hairpin RNA (shRNA) element to silence the interleukin-6 (IL-6) gene, hypothesizing it could reduce sCRS and ICANS by alleviating monocyte activation and proinflammatory cytokine release. In a post hoc analysis of two clinical trials, we compared ssCART-19 with common CAR T-cells (cCART-19) in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). Among 87 patients, 47 received ssCART-19 and 40 received cCART-19. Grade ≥3 CRS occurred in 14.89% (7/47) of the ssCART-19 group versus 37.5% (15/40) in the cCART-19 group (p = 0.036). ICANS occurred in 4.26% (2/47) of the ssCART-19 group (all grade 1) compared to 15% (2/40) of the cCART-19 group. Patients in the ssCART-19 group showed comparable rates of treatment response (calculated with rates of complete remission and incomplete hematological recovery) were 91.49% (43/47) for ssCART-19 and 85% (34/40) for cCART-19 (p = 0.999). With a median follow-up of 21.9 months, cumulative nonrelapse mortality was 10.4% for ssCART-19 and 13.6% for cCART-19 (p = 0.33). Median overall survival was 37.17 months for ssCART-19 and 32.93 months for cCART-19 (p = 0.40). Median progression-free survival was 24.17 months for ssCART-19 and 9.33 months for cCART-19 (p = 0.23). These data support the safety and efficacy of ssCART-19 for r/r B-ALL, suggesting its potential as a promising therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
HemaSphere
HemaSphere Medicine-Hematology
CiteScore
6.10
自引率
4.50%
发文量
2776
审稿时长
7 weeks
期刊介绍: HemaSphere, as a publication, is dedicated to disseminating the outcomes of profoundly pertinent basic, translational, and clinical research endeavors within the field of hematology. The journal actively seeks robust studies that unveil novel discoveries with significant ramifications for hematology. In addition to original research, HemaSphere features review articles and guideline articles that furnish lucid synopses and discussions of emerging developments, along with recommendations for patient care. Positioned as the foremost resource in hematology, HemaSphere augments its offerings with specialized sections like HemaTopics and HemaPolicy. These segments engender insightful dialogues covering a spectrum of hematology-related topics, including digestible summaries of pivotal articles, updates on new therapies, deliberations on European policy matters, and other noteworthy news items within the field. Steering the course of HemaSphere are Editor in Chief Jan Cools and Deputy Editor in Chief Claire Harrison, alongside the guidance of an esteemed Editorial Board comprising international luminaries in both research and clinical realms, each representing diverse areas of hematologic expertise.
期刊最新文献
30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis How to diagnose acid sphingomyelinase deficiency (ASMD) and Niemann–Pick disease type C from bone marrow and peripheral blood smears GPRASP protein deficiency triggers lymphoproliferative disease by affecting B-cell differentiation Issue Information Mitochondrial retention in mature red blood cells from patients with sickle cell disease is associated with stress erythropoiesis but not with proinflammatory state
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1